B-LCL-CDG7 Cells
CAD$1,104.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | B-LCL-CDG7 is an EBV-transformed B lymphocyte cell line derived from a young boy with CDAII. CDAII is a rare genetic anaemia, affiliated to the class of CDG glycosylation disorders. CDAII patients have a defect in the COPII component SEC23B gene which is involved in the intracellular protein transport system (in particular vesicular budding from ER). The respective patient is homozygous for the mutation in this gene. Band 3 glycoprotein of erythrocyte membranes is under glycosylated by aberrant glycosylation of polylactosamine motifs of glycoproteins but not of glycosphingolipids, thus band 3 of CDA II erythrocytes have truncated hybrid-type oligosaccharides. This points to an additional defect in the Golgi glycosylation enzymes Beta-mannosidase II or Nacetylglucosaminyltransferase II. |
|---|---|
| Organism | Human |
| Tissue | Peripheral blood |
| Disease | Congenital Disorders of Glycosylation |
| Applications | Genotyping of CDG effects in immune cells, functional testing (e.g. B cell surface antigens), testing of cytotoxic drugs, mutational analysis, analysis of apoptotic mechanisms, HLA-typing, impact of defective glycosylation of distinct cellular glycoproteins on diverse functions. |
Characteristics
| Age | Child |
|---|---|
| Gender | Male |
| Ethnicity | Caucasian |
| Morphology | Round cells |
| Cell type | B lymphocyte |
| Growth properties | Suspension, Cluster |
Regulatory Data
| Citation | B-LCL-CDG7 (Cytion catalog number 302018) |
|---|---|
| Biosafety level | 2 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_A9Y3 |
Biomolecular Data
| Surface antigens | CD15 (Lewis x)(+), CD15s (sialylated Lewis x)-, CD75s (sialylated lactosaminyl Noligosccharides)+, CD173 (blood group H)-, CD174 (blood group Lewis y)-, CD175 (Tn)-, CD175s (sialylated Tn)-, CD176 (TF)+ |
|---|---|
| Antigen expression | CD19+, CD20+, CD37+, CD43+, CD44+, CD45+, CD45R0-MHC Class.I+, MHC Class II (HLA-DR)+ |
| Viruses | Transformant: EBV |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% heat-inactivated FBS |
| Subculturing | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 2 x 105 cells/ml and keep the cell concentration within the range of 1 x 105 to 5 x 105 cells/ml for optimal growth. |
| Fluid renewal | Once the medium colour turned into yellow |
| Post-Thaw Recovery | Medium |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|